Straight talk opening
Yuh need a partner weh truly get lung work. When yuh shop for a respiratory CRO, yuh move quick but yuh must check deep — study design, models, regulatory habits, data flow. Problems hide behind fancy slides; dis checklist show weh fi look fi so yuh nah waste money or time.
Define the problem yuh want dem fi solve
Say plainly what outcome yuh need: proof-of-concept on an inhaled molecule, translational PK/PD, or safety in chronic airway models. Write the primary endpoint and two back-up endpoints. If yuh cyaah describe endpoint in one sentence, vendor can’t either.
Study design and translational relevance
Ask which animal model dem use and why. Demand evidence linking model endpoints to human clinical measures. Request historical control data and assay validation. If the vendor can’t show how a lung function readout map to a clinical end, move on.
Regulatory, compliance and documentation
Check GLP/GCP status for the specific study type. Confirm SOPs for biosample handling, chain-of-custody, and data integrity. Get audit reports or corrective-action summaries for past inspections. No loose promises — require documented procedures and signature chains.
Operational capabilities and timelines
Confirm housing and inhalation exposure systems, staff experience with respiratory endpoints, and back-up plans for equipment failure. Ask for a realistic timeline with milestones and penalty or remediation language for missed critical dates. Vendors who inflate speed during sales will slow later.
Data, analysis and IP security
Specify raw data delivery format, statistical plan, and acceptance criteria before study start. Insist on data traceability from instrument to report. Clarify IP ownership and publication rights in writing. If data transfer methods aren’t encrypted and auditable, require changes.
Vendor vetting checklist
Request three recent respiratory study reports (redacted if needed), client references on similar projects, and an organizational chart showing study team. Verify subcontractor use and oversight. Ask for examples of unexpected problems they solved on respiratory projects.
Budget realism and change control
Break costs by study phase and include contingency for protocol amendments. Define change-control steps and approval authority. Flat-fee quotes without scope detail hide risk. Favor transparent, milestone-tied payments.
Common pitfalls to avoid
Don’t accept vague endpoints, verbal promises about timelines, or missing disaster recovery plans. Don’t skip a pre-study site visit or a technical kickoff with the lab scientists. Overlooking assay validation, or relying solely on third-party summaries, creates rework later.
How to judge claims — practical EEAT
Look for evidence: method validation reports, peer-reviewed papers using the vendor’s models, and named study leads with respiratory experience. Real-world anchor: the COVID-19 pandemic pushed massive attention and rapid advances in respiratory therapeutics, changing expectations for speed and transparency. Check that the vendor can show how their assays supported later clinical decisions in that context, and review materials that tie their work to respected standards for respiratory drug development. Years of published methods and reproducible datasets beat marketing claims every time.
Decision matrix (quick filter)
Score each vendor on: scientific fit, regulatory compliance, operational readiness, data quality, and cost transparency. Use a single-sheet summary for executives so technical gaps are obvious. If a vendor fails any non-negotiable item, stop the discussion.
Final synthesis
Procurement for lung studies demand straight checks, not fluff. Use the checklist: define endpoints, verify models and documentation, require auditable data, and insist on clear change control. That practical alignment — clarity on science, compliance, and delivery — is what helps teams move clean from protocol to clinic, and it’s exactly the kind of dependable capability offered through partners like KCI Biotech.
